Pyc Therapeutics Stock Current Liabilities
| PYC Stock | 1.40 0.05 3.45% |
PYC Therapeutics fundamentals help investors to digest information that contributes to PYC Therapeutics' financial success or failures. It also enables traders to predict the movement of PYC Stock. The fundamental analysis module provides a way to measure PYC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PYC Therapeutics stock.
Total Current Liabilities is likely to gain to about 9.6 M in 2024. Non Current Liabilities Total is likely to gain to about 1.1 M in 2024. PYC | Current Liabilities |
PYC Therapeutics Company Current Liabilities Analysis
PYC Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
PYC Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, PYC Therapeutics has a Current Liabilities of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Australia stocks average (which is currently at 0.0).
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
PYC Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.78) % | ||||
| Current Valuation | 587.49 M | ||||
| Shares Outstanding | 466.61 M | ||||
| Shares Owned By Insiders | 59.23 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 29.61 X | ||||
| Revenue | 22.06 M | ||||
| Gross Profit | 15.81 M | ||||
| EBITDA | (38.12 M) | ||||
| Net Income | (37.73 M) | ||||
| Cash And Equivalents | 15.57 M | ||||
| Total Debt | 1.11 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (38.59 M) | ||||
| Earnings Per Share | (0.10) X | ||||
| Target Price | 8.75 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 653.25 M | ||||
| Total Asset | 91.24 M | ||||
| Retained Earnings | (155.89 M) | ||||
| Working Capital | 76.51 M | ||||
| Net Asset | 91.24 M |
About PYC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PYC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PYC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PYC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.